PROGNOSTIC SIGNIFICANCE OF TONSL EXPRESSION AND THE HOMOLOGOUS RECOMBINATION PATHWAY IN INTERMEDIATE-RISK PROSTATE CANCER RECURRENCE

被引：0
|
作者：
So, Jonathan [1 ]
Chua, Melvin [2 ]
Lalonde, Emilie [3 ]
Mahamud, Osman [1 ]
Berlin, Alejandro [1 ]
Dal Pra, Alan [4 ]
Orain, Michele [5 ]
Hovington, Helene [6 ]
Bergeron, Alain [6 ]
Fradet, Yves [6 ]
Tetu, Bernard [5 ]
Meng, Alice [2 ]
Zhang, Junyan [2 ]
Zafarana, Gaetano [2 ]
Pintilie, Melania [2 ]
van der Kwast, Theodorus [1 ]
Fraser, Michael [2 ]
Boutros, Paul [2 ]
Bristow, Robert G. [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Ontario Inst Canc Res, Toronto, ON, Canada
[4] Univ Bern, Bern, Switzerland
[5] CHUQ, Quebec City, PQ, Canada
[6] Univ Laval, Quebec City, PQ, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2016年 / 120卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [41] Development of prognostic signatures for intermediate-risk papillary thyroid cancer
    Kevin Brennan
    Christopher Holsinger
    Chrysoula Dosiou
    John B. Sunwoo
    Haruko Akatsu
    Robert Haile
    Olivier Gevaert
    BMC Cancer, 16
  • [42] Is active surveillance safe for patients with intermediate-risk prostate cancer?
    Chung, Hoseok
    Shin, Bo Sung
    Nam, Deok-Hyun
    Chung, Hoseok
    Kim, Myung Ki
    Jung, Seung Il
    Kang, Taek Won
    Kwon, Dong Deuk
    BJU INTERNATIONAL, 2015, 116 : 4 - 4
  • [43] Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
    Overland, Maya R.
    Washington, Samuel L., III
    Carroll, Peter R.
    Cooperberg, Matthew R.
    Herlemann, Annika
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 605 - 611
  • [44] Predicting intermediate-risk prostate cancer using machine learning
    Stojadinovic, Miroslav
    Stojadinovic, Milorad
    Jankovic, Slobodan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, : 1737 - 1746
  • [45] Is there a need for supplemental XRT in intermediate-risk prostate cancer patients?
    Stone, Nelson N.
    BRACHYTHERAPY, 2013, 12 (05) : 393 - 397
  • [46] Insignificant disease among men with intermediate-risk prostate cancer
    Hong, Sung Kyu
    Vertosick, Emily
    Sjoberg, Daniel D.
    Scardino, Peter T.
    Eastham, James A.
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1417 - 1421
  • [47] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [48] Testosterone Therapy in a Man with Intermediate-risk Prostate Cancer: Pro
    Morgentaler, Abraham
    EUROPEAN UROLOGY FOCUS, 2017, 3 (4-5): : 316 - 318
  • [49] Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Diven, Marshall A.
    Tshering, Lhaden
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher
    McClure, Timothy
    Nagar, Himanshu
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [50] Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy
    Narita, Shintaro
    Mitsuzuka, Koji
    Tsuchiya, Norihiko
    Koie, Takuya
    Kawamura, Sadafumi
    Ohyama, Chikara
    Tochigi, Tatsuo
    Yamaguchi, Takuhiro
    Arai, Yoichi
    Habuchi, Tomonori
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (11) : 1029 - 1035
12345